Cover Image

Exercise training response according to baseline ferrokinetics in heart failure with preserved ejection fraction: A substudy of the TRAINING‐HF trial

Abstract Background Iron deficiency (ID) is associated with impaired functional capacity in patients with heart failure (HF), even in those with preserved ejection fraction (HFpEF). This study aimed to evaluate the effect of baseline ferrokinetics on peak oxygen consumption (peakVO2) improvement aft...

Full description

Saved in:

Bibliographic Details
Main Authors:	Patricia Palau (Author), Laura López (Author), Eloy Domínguez (Author), Rafael de LaEspriella (Author), Raquel Campuzano (Author), Almudena Castro (Author), Gema Miñana (Author), Agustin Fernández‐Cisnal (Author), Juan Sanchis (Author), Julio Núñez (Author)
Format:	Book
Published:	Wiley, 2024-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Noninvasive imaging assessment of rehabilitation therapy in heart failure with preserved and reduced left ventricular ejection fraction (IMAGING-REHAB-HF): design and rationale
by: Fernando Bianchini Cardoso, et al.
Published: (2019)

Association of Chronic Kidney Disease with Preserved Ejection Fraction Heart Failure Is Independent of Baseline Cardiac Function
by: Thomas A. Mavrakanas, et al.
Published: (2019)

Polypill Eligibility for Patients with Heart Failure with Reduced Ejection Fraction in the ASIAN-HF Registry: A Cross-Sectional Analysis
by: Aishwarya Vijay, et al.
Published: (2023)

The relationship between ferrokinetic parameters and the state of cardiac remodeling in patients with coronary artery disease with concomitant iron deficiency
by: M. O. Konovalova, et al.
Published: (2023)

Pediatric heart failure with preserved ejection fraction, a review
by: Sophie Quennelle, et al.
Published: (2023)

Bistatic HF Radar
Published: (2020)

Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR‐Preserved
by: Andrew J.S. Coats, et al.
Published: (2024)

Effects of Endurance Exercise Training and Crataegus Extract WS® 1442 in Patients with Heart Failure with Preserved Ejection Fraction - A Randomized Controlled Trial
by: Sascha Härtel, et al.
Published: (2014)

Eficacia de la realidad virtual en la reducción de la ansiedad en la revascularización de las OTC: diseño del ensayo ReViCTO
by: Agustín Fernández-Cisnal, et al.
Published: (2023)

NADPH Oxidases in Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction
by: James P. Teuber, et al.
Published: (2022)

Heart failure with preserved ejection fraction (HFpEF): Implications for the anesthesiologists
by: Ajmer Singh, et al.
Published: (2018)

Total Spectrum Power and Power of HF Waves in Athletes Depending on the Phase of the Training Year and Other Factors (Review)
by: Denis A. Kataev, et al.
Published: (2024)

Outpatient services and primary care: scoping review, substudies and international comparisons
by: Eleanor Winpenny, et al.
Published: (2016)

THE ROLE OF FACTORS AFFECTING THE FORMATION OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION
by: M. V. Kurkina, et al.
Published: (2017)

DIASTOLIC LEFT VENTRICULAR DYSFUNCTION AND HEART FAILURE WITH PRESERVED EJECTION FRACTION IN ELDERLY
by: CALENICI Oleg, et al.
Published: (2022)

Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors
by: Artem Ovchinnikov, et al.
Published: (2022)

Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
by: Jahanzeb Malik, et al.
Published: (2021)

Dapagliflozin versus sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fraction
by: Ronen Arbel, et al.
Published: (2024)

ATRIAL FIBRILLATION AND ARTERIAL HYPERTENSION: GENDER DIFFERENCES OF VENTRICULOATRIAL REMODELING WITH PRESERVED EJECTION FRACTION
by: Zh. D. Kobalava, et al.
Published: (2017)

Pharmacological Tuning of Adenosine Signal Nuances Underlying Heart Failure With Preserved Ejection Fraction
by: Alexandrina Campos-Martins, et al.
Published: (2021)

Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction
by: Koichiro Matsumura MD, et al.
Published: (2023)

The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction
by: Lindsay Brust-Sisti, et al.
Published: (2022)

Association Between Hyperaldosteronemia and Electrophysiological Myocardial Activity in Heart Failure with Preserved Ejection Fraction
by: A. N. Shevelok
Published: (2020)

Evidence-based Appraisal of the DAPA-HF Trial
by: Anthony Sengul, et al.
Published: (2020)

Heart Failure with Preserved Ejection Fraction in a Postpartum Patient with Superimposed Preeclampsia and COVID-19
by: Rachel G. Sinkey, et al.
Published: (2020)

Heart Failure with Preserved and Reduced Ejection Fraction in Hemodialysis Patients: Prevalence, Disease Prediction and Prognosis
by: Marlies Antlanger, et al.
Published: (2017)

Prognostic of NT-proBNP in heart failure patients with preserved, mid and reduced ejection fraction
by: Reynie Leonel Reinoso Gonella, et al.
Published: (2021)

Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction
by: Liyun Zhang, et al.
Published: (2021)

Subclinical Hypothyroidism Predicted Adverse Cardiovascular Events in Patients with Ejection Fraction Preserved Heart Failure
by: Tan Q, et al.
Published: (2024)

Uncoupling of glycolysis from glucose oxidation accompanies the development of heart failure with preserved ejection fraction
by: Natasha Fillmore, et al.
Published: (2018)

Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
by: Yi Tang, et al.
Published: (2022)

Phosphodiesterase inhibitor for heart failure with preserved ejection fraction: A systematic review and meta-analysis
by: Zhu Chen, et al.
Published: (2022)

Beta-blockers in chronic heart failure with preserved left ventricular ejection fraction: is deprescribing possible?
by: V. D. Zakiev, et al.
Published: (2023)

Dynamics of Vascular Stiffness and Endothelial Function in Combination Therapy of Heart Failure with Preserved Ejection Fraction
by: Z. M. Akhilgova, et al.
Published: (2020)

Myeloperoxidase, a possible biomarker for the early diagnosis of cardiac diastolic dysfunction with preserved ejection fraction
by: Bogdan Ioan Coculescu, et al.
Published: (2018)

Evaluation of claims‐based computable phenotypes to identify heart failure patients with preserved ejection fraction
by: Sarah S. Cohen, et al.
Published: (2020)

Traditional Chinese medicine for heart failure with preserved ejection fraction: clinical evidence and potential mechanisms
by: Yujian Fan, et al.
Published: (2023)

A comprehensive evaluation of heart failure with preserved ejection fraction and the relationship to atrial fibrillation in Turkey
by: Muhammed Keskin
Published: (2020)

Prognostic Value of Inflammatory Cytokines in Predicting Hospital Readmissions in Heart Failure with Preserved Ejection Fraction
by: Zhao Z, et al.
Published: (2024)

Resistant Hypertension From Renal Artery Stenosis Leading to Heart Failure With Preserved Ejection Fraction
by: Motasem Alyamani MBBS, et al.
Published: (2018)